3 Upcoming Monster Stocks to Buy Right Now

California’s giant redwoods were once tiny seedlings or seeds. Similarly, the world’s largest companies were once much smaller. Trees and companies can grow significantly over time—at least some of them.

Three Motley Fool contributors think they’ve found it biotechnological actions that have the potential to become much bigger. Here’s why they think CRISPR Therapeutics (NASDAQ: CRSP), Zeeland Pharmacy (Wholesale: ZLDP.F)And Viking Therapeutics (NASDAQ: VKTX) There are some monster stocks in the making to buy right now.

CRISPR Therapeutics: The Cogs Are in Motion

Prosper Junior Bakiny (CRISPR Therapeutics): Launching a first clinical-stage product is always a major milestone for a biotech company. That’s what happened with CRISPR Therapeutics last year. The gene editing specialist approval obtained for Casgevy, developed in collaboration with Vertex Pharmaceuticalsto treat sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT).

However, the CRISPR Therapeutics breakthrough was significant for several other reasons. Let’s mention two. First, there is a significant unmet need in the field of sickle cell disease and Down syndrome, a need that Casgevy will help fill where it is approved. Second, Casgevy became the first approved gene-editing treatment that uses the CRISPR-Cas9 gene-editing technique that earned its creators a Nobel Prize in Chemistry.

Here’s why it matters. CRISPR Therapeutics uses this technique across its entire investigational drug platform. Before Casgevy, the company had yet to prove that its technology could help drugs clear all the clinical and regulatory hurdles needed to be approved. With this win in hand, CRISPR Therapeutics can move forward with confidence. The company has many other promising candidates in its pipeline. Over the next five years, expect significant progress on the company’s programs as it generates strong, consistent revenue from Casgevy.

In short, CRISPR Therapeutics has many of the qualities needed to succeed as a biotech company: a strategic focus on ambitious targets, proven innovation capabilities, and a rich pipeline. While its market cap hovers around $5 billion at the time of writing, the stock is likely to become a much larger player.

Danish biotech with two potential growth catalysts

David Jagielski (Zealand Pharmacy): The biggest growth stocks in the healthcare sector are those that are concerned with weight loss treatments. Zealand Pharma is a stock that may not get as much attention as other big-name players. The Danish company is not as popular as Novo Nordiskbut investors shouldn’t overlook its potential to become a huge growth stock.

The story continues

What’s exciting about Zealand Pharma is that it has not one, but two weight-loss drugs that could be game-changers for its business. Survodutide has shown positive results in treating a form of liver inflammation known as metabolic-associated steatohepatitis (MASH) in phase 2 trials. And it’s also shown that it can help people lose about 19% of their body weight after age 46…